Regulatory System of Research on New Infectious Diseases the Thai Perspective Soraj Hongladarom, Center for Ethics of Science and Technology Chulalongkorn.

Slides:



Advertisements
Similar presentations
National Herbarium & Botanic Gardens of Malawi
Advertisements

July 2002 EU Conference on 3Rs Animal Experimentation - a controversial issue.
Strategies for Working with Countries – Regional and Sub-Regional Perspective and Experiences Essential Drugs and Medicines Policy WHO South-East Asia.
World Society for the Protection of Animals Indicators for Enforcement – a global perspective Enforcement of European Animal Welfare Related Legislation.
Thailand National Focal Point for IFCS Chemical Safety Section Food and Drug Administration Ministry of Public Health July 2003.
BIOETHICS: THE SUBJECT, PURPOSE AND OBJECTIVES OF THE HEALTH CARE SYSTEM. BIOETHICS OF BIOMEDICAL EXPERIMENTS. INTERNATIONAL DOCUMENTS ON BIOETHICS AND.
November 26, Fall Forum Alberta’s Pharmaceutical Strategy and Programs Policy Recommendations.
Panel themes of the International Conference “Europe against Counterfeit Medicines” G.N. Gildeeva, Deputy head of the Department of Registration of Medicines.
Medical Ethics Lecturer :Noha Alaggad
WHO Good Governance for Medicines programme Technical Briefing Seminar 19 November 2009, Geneva Dr Guitelle Baghdadi-Sabeti Department of Essential Medicines.
John J Downes International Travel and Tourism Law Consultant
Preparing an Essential-Use Nomination for CFC MDIs: The U.S. Experience Consultative Meeting on Essential Use Nominations Bangkok, Thailand 6 July 2008.
Use of Children as Research Subjects What information should be provided for an FP7 ethical review?
Population Health for Health Professionals. Module 1 The Perspective of Public Health.
Regulation, Law and Animal Health and Welfare The role of legal regulation GOLD John McEldowney, School of Law, University of Warwick.
CUMC IRB Investigator Meeting November 9, 2004 Research Use of Stored Data and Tissues.
LIMITLESS POTENTIAL | LIMITLESS OPPORTUNITIES | LIMITLESS IMPACT Copyright University of Reading IMPACT AND THE LIFE SCIENCES Anthony Atkin (Research Impact.
The History of Public Health
HSP progress in Taiwan 2009 Benjamin I. Kuo, MD, DrPH, CIP Secretariat, Joint Institutional Review Board.
Aflatoxins in Zimbabwe Legislative Frameworks Against Level of Awareness A Perspective from a Laboratory Paper presented by Nozipo Nziramasanga At Huang.
PUBLIC HEALTH. Public Health Vocab _________________: One who advocates or resorts to measures beyond the norm. ___________________(____): Those that.
ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )
Medical Professionalism and its Relationship to Public Health: Physician Advocacy and State Public Health Policy Thomas Kellogg Program Officer and Advisor.
The Eighth Asian Bioethics Conference Biotechnology, Culture, and Human Values in Asia and Beyond Confidentiality and Genetic data: Ethical and Legal Rights.
Capacity Building in Research Ethics Experiences from Thailand Soraj Hongladarom Department of Philosophy, Chulalongkorn University Bangkok, Thailand.
Biosafety/ Biosecurity in Georgia Lela Bakanidze, Ph.D. National Center for Disease Control and Medical Statistics of Georgia Scientific Networking and.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Global Mobilization towards the Achievement of MDG3 Office of Women’s Affairs and Family Development Ministry of Social Development and Human Security.
5 th Inter-Agency Meeting on Coordination and Harmonization of HIV/AIDS, TB and Malaria Strategies RECOMMENDATIONS OF THE EXPERT MEETING 5-7 MARCH 2014,BRAZZAVILLE,
ACCESS TO MEDICINES - POLICY AND ISSUES
Implementing the WIPO Development Agenda: Comparing National Approaches to Promoting Coherence Between Public Policy Objectives and IP Laws ICTSD Roundtable.
The ASEAN-EU LEMLIFE Project: An Overview Soraj Hongladarom Department of Philosophy Chulalongkorn University.
1/7 Are Patients Today Sufficiently Informed? Right and Ethics 10 October 2007.
Policy and Legal Framework on Soil Contamination Management in Thailand Workshop on Strengthening Contaminated Soil Monitoring in Vietnam, November.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
THE EVOLVING ROLE OF PUBLIC HEALTH LAW IN CONTAINING INFECTIOUS DISEASE Anne Murphy, J.D. Chief Legal Counsel Illinois Department of Public Health "The.
The Thai Situation in Bioethics Soraj Hongladarom Department of Philosophy Chulalongkorn University.
OVERVIEW OF THE ROLES OF VARIOUS INSTITUTIONS AND REGULATORY FRAMEWORK FOR AFLATOXIN CONTROL IN TANZANIA RAYMOND N. WIGENGE DIRECTOR OF FOOD SAFETY TFDA.
A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)
What happens when the research is over? Researcher and funder perspectives J Whitworth Head of International Activities Wellcome Trust Global Forum on.
Session 6: Summary of Discussion A. Institutional Barriers and Potential Solutions 1. Natural environment does not have national or institutional boundaries,
Tsuyoshi Kawakami, MD, PhD Senior OSH Specialist ILO Subregional Office for East Asia Towards the elimination of asbestos-related diseases - Common challenges.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
TRADITIONAL MEDICINE LANDSCAPE IN SOUTH AFRICA
Gender Equality in Health Care Prof. Emeritus Pensri Phijaisanit President, The Women’s Health Advocacy Foundation (WHAF)
Office of Human Research Protection Georgia Health Sciences University.
Lilly Answers that Matter. Preserving the Value of Industry Interactions with Health Care Professionals Jack Harris, M.D. Vice President, U.S. Medical.
Research Ethics PPAL February, 2011 Part 2.
Trade & Access to Medicines in India Centre for Trade & Development
Third Meeting of Officials Responsible for Penitentiary and Prison Policies Washington, September 2012 Health in Detention and Prison Settings Dr.
Second Annual Medical Research Summit March 25, 2002 Washington, D.C.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
GB590 Corporate Social Responsibility Prof. Ray Kalinski By Willette Marchany Rivera December 13, 2010.
HCA 497 MART Experience Tradition /hca497mart.com FOR MORE CLASSES VISIT
Understanding Health Care Policy
Country presentations Thailand Dr
Breastfeeding is one of the best buys in global health to save lives and improve the health, social, and economic development of both individuals and Thailand.
QoL in social perspective
Promoting Socioeconomic Transformation in ASEAN
Accountabilities of health and social care practitioners
Millennium HongQiao Hotel Shanghai
Indonesia Harm Reduction Funding Tracking
AGREEMENT FOR TRANSPARENCY The Case of Mexico
FOLLOW UP WORK PLAN QUAN GIA BINH – VIET NAM
Bioethics and Responsible Leadership
Richard Laing WHO/PAU TBS 2013
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Ethical issue in medical research.
National Medicines Policies
PHARMACOVIGILANCE SYSTEM
Presentation transcript:

Regulatory System of Research on New Infectious Diseases the Thai Perspective Soraj Hongladarom, Center for Ethics of Science and Technology Chulalongkorn University Workshop on Globalization and the New Epidemics: Ethics, Security and Policy Making, Brussels, May 2006

Overview Regulation of Research Ethics in Thailand How are the New Epidemics being Handled? Ethical Issues

Research Ethics in Thailand Currently there is no national law on research ethics, though one is being drafted at the Ministry of Public Health. Ethics on human subjects conducted by medical doctors or in hospitals have to be approved by an appropriate ethical review committee. This is required by the Medical Council. Other health care professionals also have their own guidelines.

There are some problems regarding the different standards of various ethical review committees. Also problems with compliance with international norms. Since the regulation is currently part of professional code, those outside of the profession are not regulated (though the new law is designed to change this.) As for the new infectious diseases, there has been some research on the virology and the infection mechanisms, but not much on the social and ethical implications.

Thailand has received recognition for its efficiency in fighting the new diseases. Various government agencies are concerned: Public Health, Agriculture. Many factors: dedicated personnel, timely responses, openness, funding. Coping with the New Epidemics

However, there are currently no regulations concerning research on the new epidemics. Most effort has been concentrated on monitoring, prevention and providing awareness to the public. There is very little research on how globalization as a social and economic phenomenon is related with the new epidemics either. Problems with reporting - at first there was a reluctance to report, but after international and domestic pressure the authorities have been very open. Still there are conflicts between poultry industry and the govt. - especially those in traditional farms.

Ethical Issues Global justice Since this is a global phenomenon, what should the richer countries be doing to help? Call for more interaction, collaboration, funding, expertise support. The diseases usually spread from the poorer countries to the richer ones. It seems that only when the diseases threaten the richer countries that is there a concerted effort and substantial funding and other resources toward combatting them.

Ethical Issues Protection of participants vs. Protection of public goods. There is a need to find a balance between the individual rights and protection of public goods. But the former should be taken as a default, and any infringements of them need to be clearly justified.

Ethical Issues Antiviral Drugs Currently the availability of Tamiflu is strictly regulated by the Public Health Ministry. This creates the problem of who should get the drug should the epidemic breaks out. Many fear chaos and violent conflicts. Is it ethical for the pharmaceutical companies to hold on to their patents and keep the price high?

Globalization What we need now is tighter involvement of countries, not more isolation. But the involvement should not result in exploitation or injustice.

Thank you! See you at the 8th Asian Bioethics Conference, March 19-23, 2007, Chulalongkorn University, Bangkok, Thailand.